Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

To be able to take part in this study, you would need to be 18 years old or older. You must have been diagnosed with moderate to severe rheumatoid arthritis and be starting filgotinib for the first time as part of your usual treatment, and according to what your doctor has prescribed.

Also, you need to be willing and able to use an electronic device, like a tablet or smartphone, to answer some health questions throughout the study. This helps the researchers understand how you're feeling and how the medicine is affecting you.

Generally, you can't be in another clinical study at the same time, unless it's a national health registry and your current study doctor says it's okay. This helps ensure that the information collected is clear and only related to your experience with filgotinib.

If you take part, the study will simply observe your progress while you take filgotinib as prescribed by your doctor. You won't be asked to change your medication or have extra medical procedures. You will be asked to regularly answer questions on an electronic device about how you are feeling, your symptoms, and any side effects. This is known as a patient-reported outcome (PRO). Your doctor will continue to monitor your health as usual. The total duration of your participation will depend on your treatment plan with filgotinib, but is typically a number of months while you are on the medication.